Foundayo has moved closer to European Union authorization, but the latest decision does not mean it is already available through local health services. On 15 October 2026, EMA’s human medicines committee, the CHMP, recommended the oral medicine for adult weight management and type 2 diabetes. The European Commission decision remains pending.
The useful distinction is between three milestones: a favorable scientific opinion, permission to market the medicine, and practical access in a particular country. The October recommendation clears the first of those steps. It also brings together two different bodies of evidence, one about body weight and another about blood glucose.
What the panel recommended
According to EMA’s product record, the proposed weight-management use covers adults with a body mass index of at least 30, or at least 27 but below 30 with a weight-related condition. It includes weight loss and maintenance alongside a healthy diet and physical activity. Examples of qualifying conditions include hypertension, sleep apnea and type 2 diabetes.
The proposed diabetes indication addresses adults whose type 2 diabetes is insufficiently controlled. It allows use alone when metformin is inappropriate, or with other diabetes medicines, alongside diet and activity. These are the indications recommended by the committee; the final EU product information is to follow a Commission authorization.
Foundayo contains orforglipron, a small-molecule GLP-1 receptor agonist. The regulator’s announcement describes a once-daily tablet that can be taken with or without food. That administration feature may matter to someone’s routine, but it does not establish superior health outcomes. Our orforglipron profile provides background on the molecule; this report addresses the new EU regulatory step.
Why one weight-loss headline cannot describe everyone
EMA’s announcement draws on two weight-management studies totaling 4,740 adults. One involved people without type 2 diabetes; the other included people with diabetes. Its broad summary spans different doses and populations. Reading the top of that range as an expectation for every patient would erase those differences.
A more interpretable example comes from the original ATTAIN-1 abstract, published in September 2025. This randomized, double-blind trial assigned 3,127 adults without diabetes to daily investigational orforglipron or placebo, with diet and activity support, for 72 weeks. The trial registry confirms eligibility based on obesity, or overweight with a weight-related condition, and excludes diabetes.
In the original abstract’s treatment-regimen analysis, the group assigned the highest studied regimen had a mean weight change of −11.2%, compared with −2.1% for placebo. The regimen was 36 mg in the trial; that number identifies the research arm and is not a recommendation or a conversion to proposed commercial tablet strengths. The two percentages describe average changes within the respective groups, not an 11.2-percentage-point advantage over placebo.
The abstract explicitly identifies an intention-to-treat population and treatment-regimen estimand. Those labels matter: this figure should not be exchanged for a different estimate focused on continued treatment. Our guide to trial estimands explains why reports about the same medicine can give different percentages. ATTAIN-1 also cannot supply a weight-loss prediction for people with diabetes.
The diabetes evidence asks a different question
EMA describes four main diabetes studies involving 3,765 adults. Their principal measure was change in HbA1c, a marker of blood-glucose control. The studies differed in background treatment and used placebo, dapagliflozin or oral semaglutide as comparators.
That is a separate evidence program, not another way to express the ATTAIN-1 weight result. EMA’s summarized HbA1c ranges do not create a single head-to-head ranking across all those treatments. Nor does a glucose-lowering finding, by itself, demonstrate fewer heart attacks or kidney complications. Readers comparing study headlines can use our trial-reading guide to check population, comparator and outcome before comparing percentages.
A tablet still brings tolerability questions
EMA identifies nausea, vomiting and diarrhea as the most common adverse effects. Its announcement says these occurred more often during dose increases and became less frequent over time. In the ATTAIN-1 abstract, adverse events led to treatment discontinuation in 5.3%–10.3% across orforglipron groups, versus 2.7% with placebo. These are discontinuations attributed to adverse events, not the percentage experiencing any side effect.
The study was funded by Eli Lilly. The available abstract supplies useful results but does not replace detailed safety tables or the final EU prescribing information. Choosing an oral route also creates a daily treatment routine; our oral-versus-injectable guide explores practical considerations without recommending a switch.
What to watch after the opinion
EMA says the opinion now goes to the European Commission for a decision on EU-wide marketing authorization. If authorization is granted, pricing and reimbursement decisions follow at national level. The announcement does not provide a country-by-country launch date, price or coverage commitment.
For someone following access, the next useful records are therefore the Commission decision, the final EU product information and the relevant national reimbursement or launch notice. A positive committee opinion is meaningful progress. It still cannot answer whether a particular prescription will be covered or filled, and it is not a reason to change an existing treatment independently.



